A
Alderaan Biotechnology
Biotech company that develops therapeutic antibodies
About Alderaan Biotechnology
Alderaan Biotechnology is a French biotechnology company established in 2017, with its headquarters in Paris. The company was founded by two prominent researchers: Professor Armand Bensussan, the head of the Skin Research Centre at Saint Louis Hospital in Paris, and Professor Daniel Olive, who leads the Immunity and Cancer team at the Institut Paoli Calmette.
Read full description
The company is focused on the development of novel therapies for cancer treatment, specifically targeting cells of the immune system. Alderaan Biotechnology is in the preclinical stage of developing monoclonal antibodies for oncology applications. Its primary area of research is in the fields of immunomodulation and immunotherapy.
A significant milestone for the company was in January 2020, when it successfully raised €18.5 million in a Series A funding round. This investment was led by Advent France Biotechnology (AFB) and Medicxi, which has provided the company with the capital to advance its research and development programs.
The business model of Alderaan Biotechnology is centered on research and development in the biotechnology sector. As a preclinical stage company, its primary clients would be larger pharmaceutical companies that would partner with or acquire its developments to take them through clinical trials and to market. The company operates in the highly specialized market of cancer immunotherapy.
At a glance
- Status
- Operational
- Founded
- 2017
- Headquarters
- Paris, France
- Employees
- 2
- Open positions
- None listed
- Dealroom signal
- 56.3/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Immune System, Spinout, Biotech and Pharma, biotech medtech and e-health, Observatoire Deeptech, DT and LS, observatoire healthtech, science-based
- Client focus
- b2b
Latest news
Press, funding announcements and product moves mentioning Alderaan Biotechnology.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Jan 2020 | $20M | $81M | AdBio partners · Medicxi | ↗ |
| SPINOUT✓Other financing | Jul 2017 | $0 | — | French National Centre for Scientific Research - CNRS · CNRS Innovation | — |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Alderaan Biotechnology is 0 monthly website visits. Alderaan Biotechnology's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
AdBio partners
Medicxi
Other known investors2 additional known investors
CNRS Innovation
French National Centre for Scientific Research - CNRS
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Alderaan Biotechnology on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Alderaan Biotechnology’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.